AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to ...

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...

The pharmaceutical giant raised its full-year guidance after third-quarter revenue and core earnings per share topped ...

AstraZeneca raised its full-year guidance after third-quarter results topped analysts’ expectations, boosted by its cancer ...

AstraZeneca said it plans to pump $2 billion in new investment into the U.S., one of the first major foreign companies to ...

AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but ...

AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

Full Year Guidance Upgrade (2024): Total revenue and core EPS expected to grow by high 10s percentage. AstraZeneca PLC ...

AstraZeneca Plc (NASDAQ: AZN) Q3 2024 Earnings Call Nov 12, 2024, 9:00 a.m. ET ...

The decision to pause its investment in Britain came as AstraZeneca announced plans to spend $3.5bn (£2.7bn) expanding its US ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...